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Purpose: Questions remain about whether moderately hypofractionated whole-breast irradiation is appropriate for patients
with triple-negative breast cancer.
Methods and Materials: Using the prospective database of a multicenter, collaborative quality improvement consortium, we
identiﬁed patients with node-negative, triple-negative breast cancer who received whole-breast irradiation with either moderate
hypofractionation or conventional fractionation. Using inverse probability of treatment weighting (IPTW), we compared
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outcomes using the Kaplan-Meier product-limit estimation method with Cox regression models estimating the hazard ratio for
time-to-event endpoints between groups.
Results: The sample included 538 patients treated at 18 centers in 1 state in the United States, of whom 307 received conventionally fractionated whole-breast irradiation and 231 received moderately hypofractionated whole-breast irradiation. The
median follow-up time was 5.0 years (95% conﬁdence interval [CI], 4.77-5.15 years). The 5-year IPTW estimates for freedom
from local recurrence were 93.6% (95% CI, 87.8%-96.7%) in the moderate hypofractionation group and 94.4% (95% CI,
90.3%-96.8%) in the conventional fractionation group. The hazard ratio was 1.05 (95% CI, 0.51-2.17; P = .89). The 5-year
IPTW estimates for recurrence-free survival were 87.8% (95% CI, 81.0%-92.4%) in the moderate hypofractionation group and
88.4% (95% CI 83.2%-92.1%) in the conventional fractionation group. The hazard ratio was 1.02 (95% CI, 0.62-1.67; P = .95).
The 5-year IPTW estimates for overall survival were 96.6% (95% CI, 92.0%-98.5%) in the moderate hypofractionation group
and 93.4% (95% CI, 88.7%-96.1%) in the conventional fractionation group. The hazard ratio was 0.65 (95% CI, 0.30-1.42;
P = .28).
Conclusions: Analysis of outcomes in this large observational cohort of patients with triple-negative, node-negative breast
cancer treated with whole-breast irradiation revealed no differences by dose fractionation. This adds evidence to support the
use of moderate hypofractionation in patients with triple-negative disease. Ó 2021 Elsevier Inc. All rights reserved.

Introduction
Whole-breast moderate hypofractionation is a less costly
and less burdensome approach to adjuvant radiation therapy for women with breast cancer, requiring only 3 weeks
(15-16 fractions to 40-42.5 Gy), compared with conventional fractionation, which requires 5 weeks or longer (5050.4 Gy in 25-28 fractions). Large randomized trials from
Canada1 and the United Kingdom2 established the overall
safety and efﬁcacy of whole-breast moderate hypofractionation among patients with early-stage invasive breast cancer,
leading clinical practice guidelines to embrace this as the
preferred approach for whole-breast irradiation.3
Questions have lingered, however,4 particularly regarding the appropriateness of moderate hypofractionation
among patients with triple-negative disease. Breast and
prostate cancers may generally have a lower alpha-beta
ratio than the head and neck squamous cell carcinomas
that were evaluated to derive an initial understanding of
sensitivity to dose fractionation.5 However, questions
remain about whether the lower alpha-beta ratio is speciﬁc
to hormone-sensitive subtypes, which constitute the majority of these cancers, and whether using a higher dose per
fraction compared with a lower total dose as prescribed by
modern schedules of moderate hypofractionation is also
equally effective in triple-negative cancers. Existing data to
address these questions are limited in that the large British
trials did not collect subtype information. Therefore, the
only evidence describing subtype-speciﬁc outcomes from
randomized comparison to inform the most recent American Society for Radiation Oncology (ASTRO) guidelines
used data from a subset of patients enrolled on a Canadian
(Ontario Clinical Oncology Group [OCOG]) randomized
trial.6 In that analysis, breast cancer subtype (luminal A,
luminal B, HER2 enriched, and basal) was measured using
immunohistochemistry and ﬂuorescence in situ hybridization. Risk of local recurrence did not differ signiﬁcantly by
treatment arm when stratiﬁed by molecular subtype, but

the point estimates reported were in the direction of
improved outcomes with hypofractionation for luminal A
tumors (hazard ratio [HR], 0.56; 95% conﬁdence interval
[CI], 0.24-1.33), whereas the point estimate was in the
opposite direction for those with basal (triple-negative) disease (HR, 1.27; 95% CI, 0.21-7.58). Although this interaction was not statistically signiﬁcant, the comprehensive
ASTRO consensus guideline on whole-breast fractionation
emphasized the limitations of existing evidence and importance of additional research in this area because of the low
power to detect an interaction between subtype and treatment arm based on the size of the subgroups in the OCOG
analysis, which included only 125 patients with basal
tumors.7
Since the publication of the aforementioned guideline,
informative data have emerged from 2 additional trials.
Rates of local recurrence were similar after conventional
fractionation and moderate hypofractionation in the subgroup of 77 patients with triple-negative disease in a randomized trial from China8 and in a subgroup of 188
patients with triple-negative disease in a randomized trial
from Denmark, Germany, and Norway.9 In an editorial
accompanying the publication of the trials, Abram Recht
noted that these contributions help to advance understanding but maintained that “there is not yet sufﬁcient evidence
to conﬁdently reach a verdict on many of the important
questions outlined above [including whether moderate
hypofractionation is equally effective in patients with triple-negative disease]. Ongoing and future trials and retrospective analyses of existing studies will need to focus on
those questions.”10 One such study was recently led using a
large prospective observational cohort from Canada, which
included 603 patients with triple-negative cancer, ﬁnding
no difference in local recurrence-free survival in those
patients.11 Using a similarly large observational cohort
from the United States, we sought to collect additional evidence to address the gap in knowledge on this important
question.
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Methods and Materials
Sample design and data collection
We queried a prospective database of a statewide collaborative quality improvement consortium that enrolls all
patients receiving whole-breast irradiation at participating
facilities. We identiﬁed 672 patients with invasive, nodenegative, triple-negative breast cancer treated between January 1, 2012, and December 31, 2018 (dates were selected to
allow a median follow-up of approximately 5 years). Because
the consortium does not follow patients for disease control,
we initiated a voluntary research study with physician leads
from 18 of the 23 centers with eligible cases, to gather disease control information.
Each of the 18 centers submitted applications to their
institutional review boards and received approval to conduct
this research study. Sites collected data using standardized
forms with anonymous identiﬁers that allowed the newly
collected information to be merged with the data already
present in the consortium database, including radiation
dose-fractionation, for centralized analysis.
The 18 centers included 573 of the 672 potential cases.
We received data for 558 cases, with 13 of 18 centers returning data for all cases and with the lowest return rate being
81.82% from 2 institutions. Furthermore, we requeried the
received cases and excluded any cases that were missing
receptor status for ER, PR, or HER2/Neu, resulting in an
exclusion of 14 additional cases. Six cases had no follow-up
information, leaving 538 cases in the ﬁnal analytical sample.

Outcomes measures
We considered 3 outcomes using time-to-event endpoints.
First, we considered freedom from local recurrence (FFLR),
with the time constructed from the date of lumpectomy
until the date of local recurrence or censored on the date of
mastectomy (for patients who elected later to have mastectomy unrelated to recurrence), death, or last known contact.
Second, we considered recurrence-free survival (RFS), with
the time constructed from the date of lumpectomy until the
ﬁrst of date of recurrence (any location) or date of death, or
censored on the date of last known contact. Finally, we
determined overall survival (OS), with the time constructed
from the date of lumpectomy until the date of death or censored on the date of last known contact.

Analytical approach
The effects of moderately hypofractionated and conventionally fractionated regimens were compared for the 3 time-toevent endpoints using the Kaplan-Meier product-limit estimation method. Because fractionation treatment decisions
were made based on provider preference and the patient’s
clinical characteristics, we expected some bias in treatment
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selection to be present in this observational sample. Comparisons in an unadjusted fashion for time-to-event endpoints
would therefore be biased by any differences in predictive
and prognostic characteristics between the treatment groups.
We assessed the degree of difference in covariates between
treatment groups using the standardized difference, ﬁnding
that several covariates had absolute difference values of 10 or
greater, suggesting signiﬁcant imbalance between groups.12
Therefore, we proceeded to implement a balancing technique,
using propensity score creation for the treatment assignment
and weighting subsequent analyses by the inverse probability
of treatment assignment to correct these imbalances.
Propensity scores were calculated using multiple variable
logistic regression with the following covariates: age groups
(<50 years, 50 to <60 years, 60 to <70 years, and 70 years or
older), race (White vs Black or other), body mass index (in kg/
m2) categories (<25, underweight/normal weight; 25 to <30,
overweight; 30 to <35, obesity I; and ≥35, obesity II/III),
comorbidity group (0, 1, 2, or 3 or more comorbidities), smoking status (never, former, or current), chemotherapy (yes or
no), T stage (0/1 vs 2/3), tumor grade (1 [well]/2 [moderately]
vs 3 [poorly differentiated]), surgical margins (close/positive vs
negative), and breast volume, modeled using a restricted cubic
spline with 5 knots spaced using the observed percentiles. The
covariates for the propensity model were chosen using subject
matter knowledge about appropriate predictive and prognostic
characteristics, and categorization was modiﬁed so extremely
small groups of patients were avoided: Black patients were
grouped with patients of other races (a very small group), certain T stages were grouped together (0 with 1 and 2 with 3),
and tumor grades were grouped (1 with 2). Propensity score
calculation requires complete information for the chosen characteristics; otherwise, the propensity score is missing. Therefore, the amount of missingness needs to remain low (<3% of
the total sample) for chosen covariates. Thus, a decision was
made not to include lymphovascular invasion, which was collected with a higher degree of missingness (16.2%). Using the
propensity model as described, propensity scores could be calculated for 520 of the 538 cases composing the analytical sample. Because the total amount of missingness for propensity
scores was low, methods to impute the limited missing data
were not necessary to implement.
Product-limit 5-year estimates for the time-to-event endpoints were created after inverse probability of treatment
weighting (IPTW). Finally, Cox regression models were created to estimate the hazard ratio for time-to-event endpoints
between groups. A sensitivity analysis restricted to cases that
received boost radiation therapy was also conducted. All statistical analyses were conducted using SAS, version 9.4 (SAS
Institute, Cary, North Carolina).

Results
Of the 538 cases in the analytical sample, 307 received conventionally fractionated whole-breast irradiation and 231 received
moderately hypofractionated whole-breast irradiation. A large
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Table 1

Key Patient, Treatment, and Tumor Characteristics

Summary

y

82 (15.24)
146 (27.14)
163 (30.30)
147 (27.32)
333 (61.90)
177 (32.90)
28 (5.20)
200 (37.17)
185 (34.39)
99 (18.40)
54 (10.04)
3 (0.56)
295 (54.83)
175 (32.53)
65 (12.08)
1 (0.19)
132 (24.54)
405 (75.28)
362 (67.29)
176 (32.71)
141 (26.21)
152 (28.25)
130 (24.16)
73 (13.57)
42 (7.81)
7 (1.30)
71 (13.20)
451 (83.83)
9 (1.67)
6 (1.12)
16 (2.97)
103 (19.14)
413 (76.77)
1130.72 (997.4)
[684.40 - 1483.10]

CWBI
66 (21.50)
90 (29.32)
101 (32.90)
50 (16.29)
173 (56.35)
113 (36.81)
21 (6.84)
119 (38.76)
105 (34.20)
52 (16.94)
31 (10.10)
2 (0.65)
172 (56.03)
96 (31.27)
37 (12.05)
41 (13.36)
266 (86.64)
196 (63.84)
111 (36.16)
64 (20.85)
81 (26.38)
89 (28.99)
45 (14.66)
28 (9.12)
6 (1.95)
37 (12.05)
261 (85.02)
3 (0.98)
3 (0.98)
5 (1.63)
51 (16.61)
248 (80.78)
1205.51 (1067.65)
[702.10 - 1575.90]

AWBI
16 (6.93)
56 (24.24)
62 (26.84)
97 (41.99)
160 (69.26)
64 (27.71)
7 (3.03)
81 (35.06)
80 (34.63)
47 (20.35)
23 (9.96)
1 (0.43)
123 (53.25)
79 (34.20)
28 (12.12)
1 (0.43)
91 (39.39)
139 (60.17)
166 (71.86)
65 (28.14)
77 (33.33)
71 (30.74)
41 (17.75)
28 (12.12)
14 (6.06)
1 (0.43)
34 (14.72)
190 (82.25)
6 (2.60)
3 (1.30)
11 (4.76)
52 (22.51)
165 (71.43)
1031.66 (906)
[627.00 - 1359.30]

D is the Standardized difference. Values of 10 or above suggest signiﬁcant imbalance between fractionation groups.
IPTW is the Inverse Probability of Treatment Weighting.
2
IQR is the Interquartile range, value for the 25th and 75th percentiles are reported.
z

Dy
-42.672
-11.476
-13.268
58.976
26.958
-19.565
-17.658
-7.667
0.905
8.760
-0.469
-2.977
-5.585
6.245
0.212
.
61.852
-62.800
17.231
-17.231
28.377
9.645
-26.801
-7.454
-11.573
-14.045
7.837
-7.479
12.252
3.032
17.886
14.911
-22.066
-27.570

ALL

CWBI

AWBI

82 (15.96)
148 (28.50)
153 (29.47)
135 (26.07)
313 (60.20)
176 (33.96)
30 (5.84)
198 (38.16)
172 (33.08)
97 (18.76)
51 (9.99)

46 (15.75)
85 (28.86)
88 (30.04)
74 (25.35)
178 (60.44)
98 (33.41)
18 (6.15)
110 (37.59)
97 (33.19)
56 (19.09)
29 (10.13)

36 (16.23)
63 (28.03)
64 (28.73)
60 (27.00)
134 (59.88)
78 (34.69)
12 (5.43)
87 (38.91)
74 (32.95)
41 (18.33)
22 (9.81)

290 (55.92)
166 (32.10)
62 (11.99)

163 (55.42)
95 (32.44)
35 (12.14)

127 (56.58)
71 (31.64)
26 (11.78)

119 (23.05)
400 (76.95)
340 (65.53)
179 (34.47)
130 (25.11)
150 (28.95)
132 (25.57)
65 (12.64)
40 (7.73)

65 (22.32)
229 (77.68)
195 (66.26)
99 (33.74)
73 (24.82)
85 (29.11)
74 (25.32)
36 (12.48)
24 (8.27)

53 (23.99)
171 (76.01)
145 (64.57)
79 (35.43)
57 (25.50)
64 (28.74)
58 (25.89)
28 (12.85)
15 (7.03)

65 (12.65)
445 (85.76)
8 (1.59)

37 (12.63)
254 (86.31)
3 (1.06)

28 (12.69)
191 (85.03)
5 (2.28)

15 (3.03)
97 (18.74)
406 (78.23)
1125.84 (1008.5)
[657.20 - 1453.70]

8 (2.77)
54 (18.45)
232 (78.78)
1134 (1008.5)
[674.50 - 1470.60]

7 (3.37)
43 (19.12)
174 (77.51)
1115.15 (1006.9)
[627.00 - 1401.60]

Dy
1.330
-1.844
-2.866
3.754
-1.137
2.685
-3.063
2.711
-0.511
-1.955
-1.049
.
2.341
-1.727
-1.097
.
3.956
-3.956
-3.542
3.542
1.574
-0.811
1.292
1.093
-4.677
.
0.182
-3.643
9.496
.
3.440
1.715
-3.057
-2.973
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Age group: Age < 50
N (%)
Age group: 50 <= Age < 60
N (%)
Age group 60 <= Age < 70
N (%)
Age group: 70 <= Age
N (%)
Race: 1 = White
N (%)
Race: 2 = Black
N (%)
Race: 3 = Other
N (%)
Comorbidity group: 0
N (%)
Comorbidity group: 1
N (%)
Comorbidity group: 2
N (%)
Comorbidity group: 3+
N (%)
Smoking Status: Missing
N (%)
Smoking Status: Never
N (%)
Smoking Status: Former
N (%)
Smoking Status: Current
N (%)
Chemotherapy: Missing
N (%)
Chemotherapy: No
N (%)
Chemotherapy: Yes
N (%)
T-stage: 0/1
N (%)
T-stage: 2/3
N (%)
BMI category: Underweight/Normal <25
N (%)
BMI category: Overweight 25-<30
N (%)
BMI category: Obesity I 30-<35
N (%)
BMI category: Obesity II 35-<40
N (%)
BMI category: Obesity III >40
N (%)
Margin Status: Missing
N (%)
Margin Status: Close
N (%)
Margin Status: Negative
N (%)
Margin Status: Positive
N (%)
Tumor grade: Missing
N (%)
Tumor grade: 1
N (%)
Tumor grade: 2
N (%)
Tumor grade: 3
N (%)
Breast volume: Continuous
Mean (Median)
[IQR2]

ALL
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Freedom from local recurrence—inverse probability of treatment weight adjusted.

majority of these cases received a boost (502 of 538 [93.3%]).
The median patient age was 63 years (60 years among patients
receiving conventional fractionation and 67 years among those
receiving moderate hypofractionation). The characteristics of
patients both before and after IPTW using the calculated propensity scores are shown in Table 1. The calculated propensity
scores had sufﬁcient overlap between the populations receiving
moderate hypofractionation and conventional fractionation,
and when converted into inverse probability weights for the
treatment received, all patient weights were <3, suggesting no
unduly inﬂuential cases for weighted analyses. Furthermore, it
was observed from the weighted sample description that balance in the covariates was obtained through propensity
weighting.
The overall study median follow-up time was 5.0 years
(95% CI, 4.77-5.15 years), as calculated using the reverse
censoring method of the product-limit OS estimate. The
median follow-up time was 5.4 years (95% CI, 5.13-5.75
years) for conventional cases and 4.3 years (95% CI, 3.914.57 years) for hypofractionation cases.
The 5-year IPTW estimates for FFLR were 93.6% (95%
CI, 87.8%-96.7%) in the moderate hypofractionation group
and 94.4% (95% CI, 90.3%-96.8%) in the conventional fractionation group. The HR was 1.05 (95% CI, 0.51-2.17;
P = .89) (Fig. 1).

The 5-year IPTW estimates for RFS were 87.8% (95% CI,
81.0%-92.4%) in the moderate hypofractionation group and
88.4% (95% CI, 83.2%-92.1%) in the conventional fractionation group. The hazard ratio was 1.02 (95% CI, 0.62-1.67;
P = .95) (Fig. 2).
The 5-year IPTW estimates for OS were 96.6% (95% CI,
92.0%-98.5%) in the moderate hypofractionation group and
93.4% (95% CI, 88.7%-96.1%) in the conventional fractionation group. The HR was 0.65 (95% CI, 0.30-1.42; P = .28)
(Fig. 3).
Of the 538 cases, 502 received a boost (301 of 307 in the
conventional fractionation group and 201 of 231 in the
moderate hypofractionation group). Only 1 patient who did
not receive boost experienced a recurrence and only 2 died.
The estimates of FFLR, RFS, and OS were almost identical
to those in the entire sample when we conducted a sensitivity analysis restricted to the cases that received boost.

Discussion
Analysis of disease control outcomes in this large observational cohort of patients with triple-negative, node-negative
breast cancer treated with whole-breast irradiation reveals
no differences by dose fractionation. This adds meaningfully
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Fig. 2.

Recurrence-free survival—inverse probability of treatment weight adjusted.

to the body of evidence supporting the use of moderate
hypofractionation in patients with triple-negative disease.
Data now exist from several sources of information that,
taken together, are reassuring on the important question of
whether patients with triple-negative breast cancer are appropriate candidates for moderate hypofractionation. This
includes 125 patients randomized to treatment with either
conventional fractionation or moderate hypofractionation in
a Canadian trial,6 77 patients randomized in a Chinese trial,8
and 188 patients randomized in a trial from Denmark, Germany, and Norway (DBCG HYPO).9 Speciﬁcally, in the
OCOG trial, the hazard ratio comparing local recurrence outcomes of moderately hypofractionated to conventionally fractionated treatment in the 125 patients with triple-negative
disease was slightly in favor of conventional fractionation at
1.27, but with a very wide 95% CI from 0.21 to 7.58.6 In the
Chinese trial, among 77 triple-negative patients, results were
nearly identical in the 2 arms: 1 of 37 treated with moderately
hypofractionated radiation therapy and 1 of 40 treated with
conventionally fractionated radiation therapy had local recurrence (2 of 37 and 3 of 40 had locoregional recurrence).8 In
the DBCG HYPO Trial, among 188 patients who were ER
and HER2 negative, 7 of the 98 patients treated with conventional fractionation and 2 of the 90 patients treated with
hypofractionation had locoregional recurrence,9 again not

signiﬁcantly different, and this time with the point estimate
in the opposite direction from that in the OCOG analysis.
Although none of these subgroup analyses within the randomized trials revealed a signiﬁcant difference, given the
small size of these subgroup analyses, concerns remained.
An Italian cohort study that included 48 triple-negative
patients showed similar rates of relapse (21%) in patients
treated with hypofractionation and those receiving conventionally fractionated radiation.13 A larger Canadian cohort
study of 603 patients also revealed no differences in outcomes
with 10-year LRFS of 93.9% versus 92.2% for hypofractionation versus conventional fractionation (P = .47).11 The current study’s ﬁndings are consistent with these results and add
substantially to the number of patients with triple-negative
disease whose outcomes have now been compared, as advocated by leaders in the ﬁeld—including both those who developed the most recent consensus guidelines in this area
encouraging use of hypofractionation3 and those who raised
concerns about embracing hypofractionation too quickly.10
The primary limitation of this study is its observational
design. Patients who received hypofractionation had more
favorable disease characteristics and were less likely to
receive chemotherapy. These imbalances would be expected
to inﬂuence outcomes in opposite directions, with more
favorable disease characteristics biasing estimates of disease
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control upward in the hypofractionation group and lack of
chemotherapy biasing estimates downward in that same
group. Importantly, efforts were made to address confounding by these and other known prognostic covariates using
appropriate statistical techniques. Patients treated with
hypofractionation on the whole were treated slightly more
recently than those treated with conventional fractionation,
and the overall follow-up time was limited. Because triplenegative disease has lower rates of late recurrence than hormone receptor−positive disease, we believe that the 5-year
results presented here are informative. We are also reassured
by the consistency of the ﬁndings of this and the other 2
observational studies on this point with the ﬁndings of subgroup analyses from the randomized trials.

Conclusions
Hypofractionated radiation therapy in the adjuvant setting
after breast-conserving surgery for breast cancer is clearly
more convenient for patients, is less costly for both patients
and society, and appears to have fewer acute14 and late2 toxicities2 compared with conventionally fractionated regimens. Nevertheless, caution has been warranted when
considering whether its application is equally effective for

disease control in patients with the less common and more
aggressive subtype of triple-negative disease,10 which might
conceivably have different fractionation sensitivity compared with more common hormone-sensitive subtypes and
which has been shown to have a higher risk of local recurrence compared with other subtypes.15 Taken together with
other sources of information, this study provides evidence
that supports the use of hypofractionated whole-breast irradiation in triple-negative patients, as in other subtypes.
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